Overview of Octreotide Injection:

OCTORNIS Injection contains Octreotide a potent inhibitor of growth hormone, glucagon and insulin. It resembles natural somatostatin in physiological activities.

 

 

 


Octreotide is long-acting octapeptide.

OCTRONIS Injection can be used in the following conditions:

  • Acromegaly.
  • Diarrhea or flushing in patients with tumors such as carcinoid, pancreatic islet cell tumors, gastrinoma, pituitary adenoma and vasoactive intestinal peptide-secreting tumors (VIPomas).
  • Sulfonylurea poisoning.

Acromegaly:
100 mcg 3 times daily is the most commonly effective dosage, some patients require up to 500 mcg 3 times daily.
Carcinoid Tumour:
100 to 600 mcg/day in 2 to 4 divided doses during the first 2 wk of therapy.
VIPomas:
200 to 300 mcg/day in 2 to 4 divided doses during the initial 2 wk of therapy (range 150 to 750 mcg/day) to control symptoms.


Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase (an enzyme with key regulatory roles in all cells). Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.